Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635850 · ClinicalTrials.gov registry record · Phase 2
A Study of Mosliciguat in PH-ILD
A Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, sponsored by Pulmovant.
- Active
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 18
- Study locations
NCT06635850 is a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension that is active but no longer recruiting, run by Pulmovant. The registered enrollment target is 135 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The trial reports 18 study locations across 15 states.
The verdict
NCT06635850, a Phase 2 study of Cardiovascular Diseases and Pulmonary Hypertension, is active but no longer recruiting, sponsored by Pulmovant.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Conditions Studied
Interventions
- DRUG Placebo
- DEVICE Dry Powder Inhaler
- DRUG Mosliciguat
Study Locations (18)
California
- Ronald Reagan UCLA Medical Center - Los Angeles
- University of California Davis School of Medicine - Sacramento
- Harbor-UCLA Medical Center - Torrance - Torrance
North Carolina
- Duke University Health System - Duke Clinic - Durham
- PulmonIx - Greensboro
Arizona
- Arizona Pulmonary Specialists - Phoenix
Florida
- Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC - Celebration
Illinois
- Northwestern University - Chicago
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Kentucky
- Norton Pulmonary Specialists - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2024-10-29 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06635850
The ClinicalTrials.gov registry entry for NCT06635850 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Pulmovant, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06635850 reports 18 study locations spanning 15 distinct geographic areas - top geographies include California, North Carolina, Arizona.
Frequently Asked Questions
What is clinical trial NCT06635850 about?
NCT06635850 is a clinical study titled "A Study of Mosliciguat in PH-ILD". This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
What is the current status of trial NCT06635850?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2024-10-29. Estimated completion is 2028-01.
What conditions does trial NCT06635850 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Pulmonary Hypertension, Vascular Diseases, Interstitial Lung Disease, Lung Diseases.
What interventions are being tested in trial NCT06635850?
The interventions under investigation include: Placebo (DRUG), Dry Powder Inhaler (DEVICE), Mosliciguat (DRUG).
Who is sponsoring clinical trial NCT06635850?
This trial is sponsored by Pulmovant, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635850 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.